Low concentration of metformin induces a p53-dependent senescence in hepatoma cells via activation of the AMPK pathway

Yi,Gao; He,Zhimin; Zhou,Xinke; Xian,Lewu; Yuan,Taize; Jia,Xiaoting; Hong,Jian; He,Lu; Liu,Jifang

doi:10.3892/ijo.2013.2077

Low concentration of metformin induces a p53-dependent senescence in hepatoma cells via activation of the AMPK pathway

Authors:
- Gao Yi
- Zhimin He
- Xinke Zhou
- Lewu Xian
- Taize Yuan
- Xiaoting Jia
- Jian Hong
- Lu He
- Jifang Liu
View Affiliations

Affiliations: Department of Intensive Care Unit, Affiliated Tumor Hospital of Guangzhou Medical University, Guangzhou 510095, Guangdong, P.R. China, Department of Cancer Research, Affiliated Tumor Hospital of Guangzhou Medical University, Guangzhou 510095, Guangdong, P.R. China, Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangzhou Medical University, Guangzhou 510095, Guangdong, P.R. China, Department of Radiotherapy, Affiliated Tumor Hospital of Guangzhou Medical University, Guangzhou 510095, Guangdong, P.R. China
Published online on: August 23, 2013 https://doi.org/10.3892/ijo.2013.2077
Pages: 1503-1510

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The induction of senescence for cancer treatment has provoked considerable interest recently. Metformin, a first-line drug for diabetes mellitus type 2, appears to be associated with a lower risk and improved outcomes in hepatocellular carcinoma (HCC). The mechanism involved in function of metformin in HCC is poorly understood. We show that low doses of metformin induced hepatoma cell senescence characterized by accumulation of senescence-associated β-galactosidase activity (SA-β-gal) and the senescence marker Dec1, whereas the higher doses initiated apoptotic cell death. Metformin-induced senescence was accompanied by enhanced phosphorylation levels of AMP-activated protein kinase (AMPK) and its downstream target acetyl-CoA carboxylase (ACC). The expression of acetylated p53 at Lys382 (Ac-p53) and p21 was also increased, while phosphorylation of p53 at Ser15 (p-p53), p53, p16 and pRB was rarely altered after metformin treatment. Moreover, inhibition of AMPK decreased p-AMPK, p-ACC, Ac-p53 and p21 expression, diminished SA-β-gal staining and restored hepatoma cell proliferation. In addition, p53 siRNA transfection attenuated metformin-induced SA-β-gal staining. Intriguingly, co-expression of SIRT1 and p53 dramatically reduced the levels of Ac-p53, however, low doses of metformin treatment partially reversed the effect of SIRT1 on p53 acetylation and elevated SA-β-gal activity. These observations indicate that activation of the AMPK pathway promotes senescence in hepatoma cells exposed to low concentrations of metformin in a p53-dependent manner. Further, low doses of metformin may have the potential to be used as an adjuvant to HCC therapy.

View Figures

View References

1.	Collado M, Blasco MA and Serrano M: Cellular senescence in cancer and aging. Cell. 130:223–233. 2007. View Article : Google Scholar : PubMed/NCBI
2.	Collado M and Serrano M: Senescence in tumors: evidence from mice and humans. Nat Rev Cancer. 10:51–57. 2010. View Article : Google Scholar : PubMed/NCBI
3.	Kang TW, Yevsa T, Woller N, et al: Senescence surveillance of pre-malignant hepatocytes limits live cancer development. Nature. 479:547–551. 2011. View Article : Google Scholar : PubMed/NCBI
4.	Kuilman T, Michaloglou C, Mooi WJ and Peeper DS: The essence of senescence. Genes Dev. 24:2463–2479. 2010. View Article : Google Scholar : PubMed/NCBI
5.	Dimri GP, Lee X, Basile G, et al: A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA. 92:9363–9367. 1995. View Article : Google Scholar : PubMed/NCBI
6.	Debacq-Chainiaux F, Erusalimsky JD, Campisi J and Toussaint O: Protocols to detect senescence-associated beta-galactosidase (SA-βgal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc. 4:1798–1806. 2009.PubMed/NCBI
7.	Xue W, Zender L, Miething C, et al: Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 445:656–660. 2007. View Article : Google Scholar : PubMed/NCBI
8.	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
9.	Pollak M and Gonzalez-Angulo AM: Metformin and hepatic carcinogenesis. Cancer Prev Res. 5:500–502. 2012. View Article : Google Scholar : PubMed/NCBI
10.	Qu Z, Zhang Y, Liao M, Chen Y, Zhao J and Pan Y: In vitro and in vivo antitumoral action of metformin on hepatocellular carcinoma. Hepatol Res. 42:922–933. 2012. View Article : Google Scholar : PubMed/NCBI
11.	Chen HP, Shieh JJ, Chang CC, et al: Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut. 62:606–615. 2013. View Article : Google Scholar : PubMed/NCBI
12.	Liu J, Hou M, Yuan T, et al: Enhanced cytotoxic effect of low doses of metformin combined with ionizing radiation on hepatoma cells via ATP deprivation and inhibition of DNA repair. Oncol Rep. 28:1406–1412. 2012.PubMed/NCBI
13.	Zhou G, Myers R, Li Y, Chen Y, et al: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 108:1167–1174. 2001. View Article : Google Scholar : PubMed/NCBI
14.	Ben Sahra I, Regazzetti C, Robert G, et al: Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 71:4366–4372. 2011.PubMed/NCBI
15.	Del Barco S, Vazquez-Martin A, Cufí S, et al: Metformin: multi-faceted protection against cancer. Oncotarget. 2:896–917. 2011.PubMed/NCBI
16.	Wang W, Yang X, López de Silanes I, Carling D and Gorospe M: Increased AMP:ATP ratio and AMP-activated protein kinase activity during cellular senescence linked to reduced HuR function. J Biol Chem. 278:27016–2723. 2003. View Article : Google Scholar : PubMed/NCBI
17.	Cairney CJ, Bilsland AE, Evans T, et al: Cancer cell senescence: a new frontier in drug development. Drug Discov Today. 17:269–276. 2012. View Article : Google Scholar : PubMed/NCBI
18.	Qian Y, Zhang J, Yan B and Chen X: DEC1, a basic helix-loop-helix transcription factor and a novel target gene of the p53 family, mediates p53-dependent premature senescence. J Biol Chem. 283:2896–2905. 2007. View Article : Google Scholar : PubMed/NCBI
19.	Mallette FA, Goumard S, Gaumont-Leclerc MF, Moiseeva O and Ferbeyre G: Human fibroblasts require the Rb family of tumor suppressors, but not p53, for PML-induced senescence. Oncogene. 23:91–99. 2004. View Article : Google Scholar : PubMed/NCBI
20.	Guarente L: Sir2 links chromatin silencing, metabolism and aging. Genes Dev. 14:1021–1026. 2000.PubMed/NCBI
21.	Nardella C, Clohessy JG, Alimonti A and Pandolfi PP: Pro-senescence therapy for cancer treatment. Nat Rev Cancer. 11:503–511. 2011. View Article : Google Scholar : PubMed/NCBI
22.	Acosta JC and Gil J: Senescence: a new weapon for cancer therapy. Trends Cell Biol. 22:211–219. 2012. View Article : Google Scholar : PubMed/NCBI
23.	Ewald JA, Desotelle JA, Wilding G and Jarrard DF: Therapy-induced senescence in cancer. J Natl Cancer Inst. 102:1536–1546. 2010. View Article : Google Scholar : PubMed/NCBI
24.	Aljada A and Mousa SA: Metformin and neoplasia: implications and indications. Pharmacol Ther. 133:108–115. 2012. View Article : Google Scholar : PubMed/NCBI
25.	Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH and Huang YC: Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidence in taiwanese a representative population prospective cohort study of 800,000 individuals. BMC Cancer. 11:202011. View Article : Google Scholar
26.	Zhang ZJ, Zheng ZJ, Shi R, Su Q, Jiang Q and Kip KE: Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 97:2347–2353. 2012. View Article : Google Scholar : PubMed/NCBI
27.	Zwerschke W, Mazurek S, Stöckl P, Hütter E, Eigenbrodt E and Jansen-Dürr P: Metabolic analysis of senescent human fibroblasts reveals a role for AMP in cellular senescence. Biochem J. 376:403–411. 2003. View Article : Google Scholar : PubMed/NCBI
28.	Mariño G, Ugalde AP, Salvador-Montoliu N, et al: Premature aging in mice activates a systemic metabolic response involving autophagy induction. Hum Mol Genet. 17:2196–2211. 2008.PubMed/NCBI
29.	Sung JY, Woo CH, Kang YJ, Lee KY and Choi HC: AMPK induces vascular smooth muscle cell senescence via LKB1 dependent pathway. Biochem Biophys Res Commun. 413:143–148. 2011. View Article : Google Scholar : PubMed/NCBI
30.	Imamura K, Ogura T, Kishimoto A, Kaminishi M and Esumi H: Cell cycle regulation via p53 phosphorylation by a 5′-AMP activated protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem Biophys Res Commun. 287:562–567. 2001.
31.	Jones RG, Plas DR, Kubek S, et al: AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell. 18:283–293. 2005. View Article : Google Scholar : PubMed/NCBI
32.	Luo J, Nikolaev AY, Imai S, et al: Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 107:137–148. 2001. View Article : Google Scholar : PubMed/NCBI
33.	Langley E, Pearson M, Faretta M, et al: Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 21:2383–2396. 2002. View Article : Google Scholar : PubMed/NCBI
34.	Wang Y, Liang Y and Vanhoutte PM: SIRT1 and AMPK in regulating mammalian senescence: a critical review and a working model. FEBS Lett. 585:986–994. 2011. View Article : Google Scholar : PubMed/NCBI
35.	Zu Y, Liu L, Lee MY, et al: SIRT1 promotes proliferation and prevents senescence through targeting LKB1 in primary porcine aortic endothelial cells. Circ Res. 106:1384–1393. 2010. View Article : Google Scholar : PubMed/NCBI